Clinical Trial Update: Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and efficacy of VX-661 in combination with ivacaftor in cystic fibrosis patients homozygous for the F508del-CFTR mutation was co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Ivacaftor (ivacaftor)
• VX-661 (tezacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2018-04-13